{
    "Trade/Device Name(s)": [
        "EGENS Urine Test Cup Morphine - Methamphetamine",
        "EGENS Urine Test DipCard Morphine - Methamphetamine"
    ],
    "Submitter Information": "NANTONG EGENS BIOTECHNOLOGY, LTD.",
    "510(k) Number": "K151557",
    "Predicate Device Reference 510(k) Number(s)": [
        "K142580"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DNK",
        "LAF"
    ],
    "Summary Letter Date": "June 3, 2015",
    "Summary Letter Received Date": "June 10, 2015",
    "Submission Date": "July 9, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3640",
        "21 CFR 862.3610"
    ],
    "Regulation Name(s)": [
        "Morphine test system",
        "Methamphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Morphine",
        "Methamphetamine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow assay",
        "Competitive binding"
    ],
    "Methodologies": [
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Dipcard",
        "Cup"
    ],
    "Document Summary": "FDA 510(k) summary for EGENS Urine Test Cup and DipCard Morphine - Methamphetamine rapid immunochromatographic urine test for drugs of abuse",
    "Indications for Use Summary": "Rapid qualitative detection of Morphine and Methamphetamine in human urine at cutoffs of 300 ng/mL and 1000 ng/mL, respectively; for over-the-counter and prescription in vitro diagnostic use, providing preliminary test results requiring confirmation.",
    "fda_folder": "Toxicology"
}